W
William T. Symonds
Researcher at University of Paris
Publications - 93
Citations - 16593
William T. Symonds is an academic researcher from University of Paris. The author has contributed to research in topics: Sofosbuvir & Ribavirin. The author has an hindex of 42, co-authored 93 publications receiving 16021 citations.
Papers
More filters
Journal ArticleDOI
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz,Alessandra Mangia,David L. Wyles,Maribel Rodriguez-Torres,Tarek Hassanein,Stuart C. Gordon,Michael Schultz,M. Davis,Zeid Kayali,K. Rajender Reddy,Ira M. Jacobson,Kris V. Kowdley,L. Nyberg,G. Mani Subramanian,Robert H. Hyland,Sarah Arterburn,Deyuan Jiang,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Aasim Sheikh,Zobair M. Younossi,Edward Gane +23 more
TL;DR: In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Journal ArticleDOI
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal,Stefan Zeuzem,Paul Y. Kwo,Mario Chojkier,Norman Gitlin,Massimo Puoti,Manuel Romero-Gómez,Jean-Pierre Zarski,Kosh Agarwal,Peter Buggisch,Graham R. Foster,Norbert Bräu,Maria Buti,Ira M. Jacobson,G. Mani Subramanian,Xiao Ding,Hongmei Mo,Jenny C. Yang,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,Alessandra Mangia,Patrick Marcellin +23 more
TL;DR: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.
Journal ArticleDOI
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam H. Afdhal,K. Rajender Reddy,David R. Nelson,Eric Lawitz,Stuart C. Gordon,Eugene R. Schiff,Ronald Nahass,Reem Ghalib,Norman Gitlin,Robert Herring,Jacob Lalezari,Ziad Younes,Paul J. Pockros,Adrian M. Di Bisceglie,Sanjeev Arora,G. Mani Subramanian,Yanni Zhu,Hadas Dvory-Sobol,Jenny C. Yang,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,Mark S. Sulkowski,Paul Y. Kwo +24 more
TL;DR: Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologyic response to prior interferon-based treatment.
Journal ArticleDOI
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Mark S. Sulkowski,David F. Gardiner,Maribel Rodriguez-Torres,K. Rajender Reddy,Tarek Hassanein,Ira M. Jacobson,Eric Lawitz,Anna S. Lok,Federico Hinestrosa,Paul J. Thuluvath,Howard J. Schwartz,David R. Nelson,Gregory T. Everson,Timothy Eley,Megan Wind-Rotolo,Shu-Pang Huang,Min Gao,Dennis Hernandez,Fiona McPhee,Diane Sherman,R. Hindes,William T. Symonds,Claudio Pasquinelli,Dennis M. Grasela +23 more
TL;DR: Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Journal ArticleDOI
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Kris V. Kowdley,Stuart C. Gordon,K. Rajender Reddy,Lorenzo Rossaro,David E. Bernstein,Eric Lawitz,Mitchell L. Shiffman,Eugene R. Schiff,Reem Ghalib,Michael J. Ryan,Vinod K. Rustgi,Mario Chojkier,Robert Herring,Adrian M. Di Bisceglie,Paul J. Pockros,G. Mani Subramanian,Di An,Evguenia S. Svarovskaia,Robert H. Hyland,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,David Pound,Michael W. Fried +24 more
TL;DR: Leadipasvir-sofosbuvir for 8 weeks was associated with a high rate of sustained virologic response among previously untreated patients with HCV genotype 1 infection without cirrhosis, and results indicated noninferiority of the 8-week ledipas Viral-SofosBuvir regimen.